Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

2.440 +0.070 (+2.95%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Presents Data on T Cell Engager Platform at AACR 2022
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Reports Full Year 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
Sunday Memo - Dec. 5
The market rout was worldwide last week. 
Via Talk Markets
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (... 
Via Benzinga
AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools
From AbCellera Biologics Inc.
Via Business Wire
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front... 
Via Benzinga
Lilly's Antibody Receives FDA Emergency Use Nod For Mild-To-Moderate COVID-19
The FDA on Friday authorized Eli Lilly And Co's (NYSE: LLY) COVID-19 antibody drug for people aged 12 and older at risk of severe illness. The FDA authorized... 
Via Benzinga
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
From AbCellera Biologics Inc.
Via Business Wire
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
From AbCellera Biologics Inc.
Via Business Wire
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
From AbCellera
Via Business Wire
Top Biotech Stocks: Trading Opportunities For Next Week
A security pattern traces the distinct movements of prices, which helps traders make informed trading decisions. Let's look at some biotech stock opportunities by analyzing these patterns. 
Via Talk Markets
AbCellera Announces Changes to Its Board of Directors
From AbCellera Biologics Inc.
Via Business Wire
Futures Rebound From Friday Rout As Omicron Fears Ease
S&P futures and European stocks rebounded from Friday’s selloff while Asian shares fell, as investors took comfort in reports from South Africa which said initial data doesn’t show a surge of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Lilly's COVID-19 Antibody Cocktail Scores FDA Emergency Use For Kids, Including Newborns
The FDA has expanded the Emergency Use Authorization (EUA) for Eli Lilly And Co's (NYSE: LLY) bamlanivimab and etesevimab administered together to include... 
Via Benzinga
Exposures COVID-19 Product Safety
AbCellera-Discovered Bamlanivimab Together with Etesevimab Authorized as the First and Only Antibody Therapy for Emergency Use in COVID-19 Patients Under the Age of 12
From AbCellera Biologics Inc.
Via Business Wire
AbCellera Announces the Appointment of Neil Aubuchon as Chief Commercial Officer
From AbCellera Biologics Inc.
Via Business Wire
Vaccine Stocks Ask The Unthinkable: What Happens If Today's Covid Shots Fail?
Smaller companies are working on next-generation approaches to Covid treatment. 
Via Investor's Business Daily
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Friday Markets Coverage
Today markets are suffering alongside Austria which locked down against Covid-19 again. 
Via Talk Markets
Exposures COVID-19
AbCellera Biologics Inc. (ABCL) Q3 2021 Earnings Call Transcript
ABCL earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021
Upgrades Morgan Stanley upgraded the previous rating for EQT Corp (NYSE: 
Via Benzinga
AbCellera Reports Q3 2021 Business Results
From AbCellera Biologics Inc.
Via Business Wire
How Bad Are AbCellera Biologics's Earnings? | Return On Capital Employed
Benzinga Pro data, AbCellera Biologics (NASDAQ:ABCL) reported Q2 sales of $27.64 million. Earnings fell to a loss of $7.03 million, resulting in a 104.45% decrease from last... 
Via Benzinga
AbCellera Announces Virtual Presentations at Investor Conferences in November
From AbCellera Biologics Inc.
Via Business Wire
Why AbCellera Biologics Stock Sank 21.6% in October
The biotech is now down roughly 56% across 2021's trading. 
Via The Motley Fool
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
From AbCellera Biologics Inc.
Via Business Wire
The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies
Companies working on sorely needed Covid treatments are innovating to keep up. 
Via Investor's Business Daily
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
From AbCellera Biologics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.